

## THIS ISSUE'S AUTHORS

**GREGORY S. BRIGHAM, Ph.D.**, is chief research officer and program director at Maryhaven in Columbus, Ohio. Dr. Brigham is a psychologist with more than 20 years' experience providing and managing drug abuse treatment. He is currently a Community Treatment Program principal investigator in the Ohio Valley Node of NIDA's National Drug Abuse Treatment Clinical Trials Network. His research interests focus on developing and integrating empirically supported treatment improvements and 12-step recovery-oriented drug abuse treatment.

**DOUGLAS B. MARLOWE, J.D., Ph.D.**, is a senior scientist and director of the Section on Criminal Justice Research at the Treatment Research Institute, University of Pennsylvania in Philadelphia. Dr. Marlowe is a lawyer and clinical psychologist whose research focuses on evaluating correctional diversion programs for substance-abusing offenders. He is also associate editor (pending) of the *Journal of Substance Abuse Treatment* and serves on the Editorial Board of *Criminal Justice & Behavior*.

**THOMAS NIGHTINGALE, B.S., CASAC**, is director of the Bureau of Addiction Treatment Centers overseeing New York State's 13 addiction treatment facilities. He is the past director of the Norris Addiction Treatment Center in Rochester and the Van Dyke Addiction Treatment Center in Ovid, and he has worked in the addiction field for 28 years.

**STEVEN NOVAK, M.D.**, is medical director of the Norris Addiction Treatment Center in Rochester, New York, and he is cofounder of the Nicotine Awareness Coalition of Upstate New York. Dr. Novak has worked in the addiction field for 12 years.

**PAULA D. RIGGS, M.D.**, is board certified in adult, child, and adolescent psychiatry and has added qualifications in addiction psychiatry. She is associate professor of psychiatry at the University of Colorado School of Medicine in Denver, where she is also director of psychiatric services for adolescents at the Addiction Research and Treatment Services. Dr. Riggs is also principal investigator of the Rocky Mountain Node of the National Drug Abuse Treatment Clinical Trials Network.

**STEVEN SCHWARTZ, Ph.D. (CAND.)**, CASAC, retired from his position as director of the Stutzman Addiction Treatment Center in Buffalo, New York, after serving as center director for 35 years. He has worked in the field of addictions throughout his career as an administrator and international consultant.

**JAMES R. SHARP, Ph.D.**, is a clinical psychologist and director of the Van Dyke Addiction Treatment Center in Ovid, New York. He has worked in the mental health and addiction fields for over 25 years.

## &amp; PANEL RESPONDENTS

**PATRICIA A. CHANDLER, M.D.**, is board certified in family practice and has been ASAM-certified since 1996. Dr. Chandler has years of experience caring for adolescents in the primary care and sports medicine settings, and from 2000 to 2002 she cared for patients with heroin addiction. Currently she is in private practice and is clinical assistant professor in the Department of Family Practice at the University of Texas Southwestern Medical Center in Dallas.

**ALLAN J. COHEN, M.A., MFT**, is director of research and development for Aegis Medical Systems in Canoga Park, California. Aegis operates 30 narcotic treatment programs, serving 5,000 patients daily. Mr. Cohen has worked with the criminal justice system over the past 25 years, most recently involving implementation of Proposition 36 services in the clinics and counties where Aegis Medical Systems operates. He has had extensive professional involvement with drug courts and parole and probation offices. Mr. Cohen has recently been deeply involved in NIDA's Clinical Trials Network, blending research and clinical practice.

**LIRIO S. COVEY, M.D.**, is an associate professor of clinical psychology with the Department of Psychiatry at Columbia University in New York. She directs the Smoking Cessation Research Clinic at the Columbia-Presbyterian Medical Center campus, where she is the lead investigator on a NIDA-funded study of maintenance pharmacotherapy for the prevention of smoking relapse. Her current research projects also include studies on genetic factors in nicotine dependence, smoking cessation and relapse prevention in smokers of racial/ethnic minority background, and tobacco cessation for mildly dependent smokers.

**ROBERT F. FORMAN, Ph.D.**, is assistant professor of psychology in psychiatry at the University of Pennsylvania and director of technology transfer for Philadelphia's Treatment Research Institute. Dr. Forman, who received his doctorate from Bryn Mawr College, has spent the majority of his career developing addiction treatment services and products. He has served as a consultant to several national behavioral health care organizations, and

he served on the White House Health Review Group on Mental Health and Substance Abuse. Dr. Forman is co-principal investigator of the Delaware Valley Node of NIDA's Clinical Trials Network.

**KEITH HUMPHREYS, Ph.D.**, is associate professor of psychiatry at Stanford University School of Medicine in Stanford, California, and director of the Veterans Affairs Program Evaluation and Resource Center. He studies treatments and self-help programs for substance abuse and psychiatric disorders and is actively involved in teaching addiction treatment methods to medical students, psychiatric residents, and clinical psychology interns. Dr. Humphreys has been a consultant to the White House Office on National Drug Control Policy, Center for Mental Health Services, National Institute on Alcohol Abuse and Alcoholism, and other Federal agencies.

**FRANKLIN W. INGRAM, M.Div.**, is executive director of SouthLight, a community addiction treatment program in Raleigh, North Carolina. SouthLight provides an extensive outpatient response to adolescents with substance abuse issues, whether court-ordered, school-ordered, or self-referred. Mr. Ingram has worked as a counselor with the Neighborhood Youth Corps and served as a social worker in child and adolescent counseling and family therapy.

**ANNE M. JOSEPH, M.D., M.P.H.**, is affiliated with the Transdisciplinary Tobacco Use Research Center at the University of Minnesota. She is the policy research director and principal investigator for tobacco

strategies for patients with cardiac disease. Dr. Joseph also serves as a general internist at the Minneapolis Veterans Affairs Medical Center. She has published numerous scientific articles and abstracts on the topic of tobacco control, and she is a leader in statewide tobacco control efforts by the Minnesota Smoke-Free Coalition and the Minnesota Partnership for Action Against Tobacco.

**JENNIFER MANKEY, M.P.A.**, is executive director of the Center for Network Development in Denver, Colorado. She has 30 years' experience with juvenile and adult offender programs and directed the Denver Juvenile TASC program and the Denver Juvenile Justice Integrated Treatment Network—two cross-sector collaborative projects that integrated treatment and juvenile justice strategies in order to improve outcomes for substance-abusing juvenile offenders.

**JOSEPH J. RICHARD, Jr., Ed.D.**, is staff psychologist at the Olympic Center-Preston, Inc., in Kingwood, West Virginia, a free-standing, private, for-profit residential psychiatric treatment facility for substance-dependent adolescents. At the Olympic Center he provides diagnosis and treatment of psychological disorders, psychological consultation to the treatment team, safety risk management, behavior management, liaison to insurers, referral for psychiatric evaluation, and assistance with followup monitoring of target symptoms. He is also an adjunct assistant professor to West Virginia University and Marshall University.

**STEVEN SHOPTAW, Ph.D.**, is a principal investigator with Friends Research Institute in Los Angeles and an associate research psychologist with the Integrated Substance Abuse Programs at UCLA. Over the past 10 years, Dr. Shoptaw has conducted multiple phase 2 projects investigating medication and behavior therapies for substance dependence. He recently completed a NIDA-funded study evaluating behavioral therapies (relapse prevention and contingency management, alone and in combination) for optimizing smoking cessation by tobacco smokers in a methadone maintenance program.

**J. SCOTT TONIGAN, Ph.D.**, is the senior methodologist at the Center on Alcoholism, Substance Abuse and Addictions (CASAA) in Albuquerque, New Mexico, and has been involved in an 11-year series of alcohol treatment outcome trials, including Projects MATCH, CRAFT, ARTS, REPP, and COMBINE. Dr. Tonigan is currently supervising a 10-year followup of the Albuquerque Project MATCH sample. He has a special interest in health disparity research in relation to treatment outcome and AA participation.

**WILLIAM WENDT, J.D., CAC**, is a co-principal investigator for the Rocky Mountain Regional Node of NIDA's Clinical Trials Network. He is also the CEO of Signal Behavioral Health Network, the largest managed services organization in Colorado. Mr. Wendt is an attorney and a certified addictions counselor with more than 15 years' experience as a clinician and administrator.